Current developments of intensive pulsed light treatment for dry eye disease and meibomian gland dysfunction

Vergés, Carlos; Salgado-Borges, José; Ribot, Francesc March de; Ribas, Verónica

doi:10.1080/17469899.2021.1954504

Cited by 3 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antiin ammatory properties of IPL are thought to be one of its main bene ts in tear lm homeostasis. 23 We postulate that the increase in LLT is a consequence of the improved out ow of meibum from the glands and their enhanced function and morphology, as it has been already described. 18 In both groups, LLT increased equally and on average 39% from baseline to the post-treatment visit and 30% of cases reached normal values.…”

Section: Discussionmentioning

confidence: 62%

The Benefit of Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

Marques

Marta

Baptista

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose To study the clinical benefit of low-level light therapy when associated with intense pulsed light for the treatment of meibomian gland dysfunction. Methods An observational comparative study. Sixty-two (62) subjects were assigned 1:1 to one of two treatment arms: group 1 (31 subjects, 62 eyes), intense pulsed light followed by low-level light and group 2 (31 subjects, 62 eyes) intense pulsed light alone. In both groups, treatments were performed in 3 sessions and subjects were evaluated at baseline and 3 weeks after the last treatment session. Values are shown as Δ = mean difference ± standard deviation. Results We observed a significant improvement is OSDI-12 score and lipid layer thickness, in both groups (Δ=-22.7 ± 17.5, p < 0.001 in group 1 and Δ=-23.6 ± 23.8, p < 0.001 in group 2 for OSDI and Δ=+18.6 ± 37.0, p < 0.001 in group 1 and Δ=+19.9 ± 26.4, p < 0.001 in group 2 for lipid layer thickness). Despite no differences between groups at baseline (p = 0.469), only group 1 had a significant improvement in Schirmer test (Δ = + 1.6 ± 4.8, p = 0.009 in group 1 and Δ=+1.7 ± 6.9, p = 0.057 in group 2). No significant side effects were noted. No patient in any group felt subjectively “worse” after the treatment. Conclusion Intense pulsed light seems effective and safe for the treatment of meibomian gland dysfunction, improving symptoms and the tear film lipid layer. This study shows no strong evidence of the benefit of low-level light, but it shows weak evidence that it may further improve aqueous tear production.

show abstract

Section: Discussionmentioning

confidence: 62%

The Benefit of Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

Marques

Marta

Baptista

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The anti-inflammatory properties of IPL are thought to be one of its main benefits in tear film homeostasis. 23 In fact, Choi et al found a significant decrease in 4006 inflammatory cytokines (IL-4, IL-6, IL-10, IL-17A, and TNF-a) tear concentration after IPL treatment. 21 The reduction in OSDI score was very similar between both groups (similar improvement in symptoms).…”

Section: Discussionmentioning

confidence: 98%

Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

Marques¹,

Marta²,

Baptista³

et al. 2022

OPTH

View full text Add to dashboard Cite

Purpose To study the clinical benefit of low-level light therapy when associated with intense pulsed light for the treatment of meibomian gland dysfunction. Methods An observational study. Two groups of patients that were treated with IPL were considered: group 1 (31 subjects, 62 eyes), intense pulsed light followed by low-level light therapy and group 2 (31 subjects, 62 eyes) intense pulsed light alone. In both groups, treatments were performed in 3 sessions and subjects were evaluated at baseline and 3 weeks after the last treatment session. Values are shown as mean difference ± standard deviation. Results We observed a significant improvement in OSDI-12 score and lipid layer thickness, in both groups (−22.7±17.5, p<0.001 in group 1 and −23.6±23.8, p<0.001 in group 2 for OSDI and +18.6 ± 37.0, p<0.001 in group 1 and +19.9 ± 26.4, p<0.001 in group 2 for lipid layer thickness). Despite no differences between groups at baseline (p=0.469), only group 1 had a significant improvement in Schirmer test (+1.6±4.8, p=0.009 in group 1 and +1.7±6.9, p=0.057 in group 2). No significant side effects were noted. No patient in any group felt subjectively “worse” after the treatment. Conclusion Intense pulsed light seems effective and safe for the treatment of meibomian gland dysfunction, improving symptoms and the tear film lipid layer. This study shows no strong evidence of the benefit of low-level light therapy, but it shows weak evidence that it may further improve aqueous tear production.

show abstract

“…Literature review shows that IPL is a relatively new method for the treatment of lipid-abnormal dry eye caused by MGD. IPL can relieve the symptoms and signs of MGD-related dry eye by reducing eyelid inflammation, thermal effect, sterilisation, acariasis and light regulation 55 56. With respect to the adverse effects, the majority of studies have reported that participants did not experience any significant negative effects, apart from temporary occurrences of erythema, oedema and pain.…”

Section: Discussionmentioning

confidence: 99%

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Chen,

Qin,

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionEvaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found to be beneficial in reducing signs and symptoms of dry eye.Methods and analysisA randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol ophthalmic solution eye-drops) and IPL+group (IPL combined with 3% diquafosol eye-drops). All groups will be followed up for 4 weeks. The primary outcome measures will be the non-invasive tear break-up time and the Ocular Surface Disease Index change from the baseline. The secondary outcome measures willincludeconjunctival and cornea staining with fluorescein and lissamine, meibomian gland function and secretion quality, tear film lipid layer score, tear meniscus height, conjunctival hyperemia (redness score) changes . Adverse events also will be monitored and documented.DiscussionThis study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active control group) in participants with EDE.Ethics and disseminationManagement of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study’s findings will be shared regardless of the effect’s direction.Trial registration numberNCT05694026.

show abstract

Current developments of intensive pulsed light treatment for dry eye disease and meibomian gland dysfunction

Cited by 3 publications

References 81 publications

The Benefit of Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

The Benefit of Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Contact Info

Product

Resources

About